Tesamorelin: Evidence, Mechanism, Dosing & Legal Status

Tesamorelin (Egrifta, EGRIFTA WR/SV; formerly TH9507) is a degradation-resistant synthetic analog of growth-hormone-releasing hormone that augments the body's own pulsatile growth-hormone secretion rather than supplying exogenous GH.2 Unlike most peptides marketed for fat loss and recovery, it carries regulatory-grade human evidence — but that evidence is confined to a narrow population, and the confident consumer claims outrun the data. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a prescription or protocol to follow, and not a sourcing guide. Tesamorelin is a prescription drug and is prohibited in sport at all times. Dosing figures are reported strictly as they appear in the published literature and FDA labeling, for completeness. Consult a licensed clinician before any health decision.

What is tesamorelin and how does it work?

Tesamorelin is a synthetic peptide consisting of the full 44-amino-acid sequence of human growth-hormone-releasing factor (GRF/GHRH 1-44) with an N-terminal trans-3-hexenoyl modification. This acylation sterically protects the molecule from dipeptidyl-peptidase-IV (DPP-IV) cleavage — the enzyme that rapidly degrades native GHRH — conferring greater metabolic stability and longer functional action than endogenous GHRH.23

Mechanistically, tesamorelin binds and activates the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone. GH is both anabolic and lipolytic; it acts directly on adipocytes and indirectly through hepatic and peripheral IGF-1.2 The design intent is restorative rather than supraphysiologic: it amplifies a signal upstream of the somatotroph and preserves negative feedback — somatostatin can still limit GH output and the natural pulsatile rhythm is retained — in contrast to injecting recombinant GH directly.111 The clinical consequence is preferential mobilization of visceral fat, which is more lipolytically responsive to GH, with relative sparing of subcutaneous fat. Pharmacokinetically the peptide itself has low systemic exposure (absolute SC bioavailability under 4%) and a terminal half-life near 11 minutes, yet the downstream GH pulse gives a longer pharmacodynamic tail that permits once-daily dosing.2

What is the evidence by indication?

The honest summary is that tesamorelin's evidence quality drops sharply as you move away from HIV-associated lipodystrophy. The table below grades each indication on the standard A-to-D human-evidence scale.

HIV visceral fat (Grade A). This is the only indication with regulatory-grade evidence. In the pivotal NEJM 2007 trial, 412 HIV patients with central fat accumulation were randomized to tesamorelin 2 mg SC daily versus placebo for 26 weeks: visceral adipose tissue fell 15.2% with tesamorelin versus a 5.0% increase on placebo, and triglycerides dropped about 50 mg/dL while subcutaneous fat was largely spared.1 A second 26-week Phase 3 trial in 404 patients reproduced the ~15-18% VAT reduction, supporting approval.12 A 2026 meta-analysis of RCTs confirmed a significant VAT reduction (mean difference about -27.7 cm-squared, 95% CI -38.4 to -17.1, p<0.001) with concurrent reductions in trunk fat, waist circumference, and hepatic fat.10 Critically, the effect is maintenance-dependent — VAT returns toward baseline within about three months of stopping.9

HIV-NAFLD liver fat (Grade A/B). In the Stanley Lancet HIV 2019 trial, 61 adults with HIV and hepatic steatosis were randomized to tesamorelin 2 mg SC daily versus placebo for 12 months. Hepatic fat fraction fell with an absolute effect of -4.1% (a -37% relative reduction, p=0.016); 35% of tesamorelin versus 4% of placebo patients reached a liver-fat fraction under 5%; and on paired biopsy, tesamorelin recipients were significantly less likely to experience fibrosis progression (10% vs 37%, p=0.044) — clinically meaningful because fibrosis stage is the strongest predictor of NAFLD mortality.45 An earlier pilot first signaled the liver-fat benefit.6 Because this is one well-designed RCT, not yet replicated and not demonstrated in non-HIV MASLD, it is graded A for HIV-NAFLD but should not be generalized.

Cognition (Grade B). In the Baker Archives of Neurology 2012 trial, 152 adults aged 55-87 (66 with amnestic MCI) received tesamorelin 1 mg SC nightly or placebo for 20 weeks. Executive function improved significantly (p=0.005), while verbal memory showed only a non-significant trend; the cognitive effect disappeared after adjusting for IGF-1, implicating the GH/IGF-1 axis.7 A neurochemical substudy reported increased brain GABA after GHRH administration.8 This is a single, methodologically sound RCT — promising but unconfirmed, with no Phase 3 cognition program. The full enrollment detail is registered at ClinicalTrials.gov and summarized in the primary publication.

What doses appear in the literature?

Reported strictly as information, not a protocol. The registrational and trial dose was 2 mg SC once daily — the dose used in the NEJM 2007 pivotal trial, the pooled Phase 3 analysis, and the Stanley NAFLD trials.14 The current FDA product, EGRIFTA WR, is 1.28 mg SC once daily (0.16 mL of reconstituted solution), injected into the abdomen with site rotation; one 11.6 mg vial reconstituted with 1.3 mL bacteriostatic water yields 8 mg/mL and provides seven daily doses, so this F8 formulation requires only weekly reconstitution versus daily for the older EGRIFTA SV.23 The prior products were original Egrifta at 2 mg daily (2010) and EGRIFTA SV at 1.4 mg daily (2019); WR and SV are not substitutable.2 The aging-cognition trial used 1 mg SC nightly, 30 minutes before bedtime, for 20 weeks.7 In all cases the drug is supplied as a lyophilized powder reconstituted immediately before SC injection, and the benefit is maintenance-dependent.2

How safe is tesamorelin?

The most common adverse reactions on the FDA label were injection-site reactions (about 25% vs 14% in the first 26 weeks), arthralgia, pain in extremity, myalgia, peripheral edema, and paresthesia — consistent with GH/IGF-1 physiology and often transient.23 Two findings demand monitoring. IGF-1 elevation was common (about 47% of patients exceeded 2 SDS and 36% exceeded 3 SDS at 26 weeks), warranting periodic IGF-1 checks and possible discontinuation for persistent elevation.3 Glucose intolerance also occurred (HbA1c reaching 6.5% or higher in about 5% vs 1% on placebo, hazard ratio ~3.3) — though notably the dedicated NAFLD RCT found no between-group glycemic difference at 12 months, suggesting the effect is population- and monitoring-dependent.24

The dominant theoretical concern is neoplasm risk: because tesamorelin raises endogenous GH and IGF-1, both growth factors, the label requires any preexisting malignancy to be inactive and treatment complete before starting, with discontinuation if malignancy recurs.2 Tesamorelin is contraindicated where the hypothalamic-pituitary axis is disrupted (the drug needs functional somatotrophs), in active malignancy, in known hypersensitivity, and in pregnancy — animal data showed hydrocephaly in rat offspring at roughly 2-4x clinical exposure.23

What is the FDA and WADA status in 2026?

Tesamorelin is FDA-approved with a single indication — reduction of excess abdominal/visceral fat in HIV-infected adults with lipodystrophy. Initial approval was November 10, 2010 (Egrifta); EGRIFTA SV followed in 2019; the current F8 formulation EGRIFTA WR was approved March 25, 2025, offering daily injection with only weekly reconstitution.1314 It is explicitly not approved for weight loss, body recomposition, anti-aging, or non-HIV NAFLD, and the label states long-term cardiovascular safety is unestablished.3 As an approved drug it is normally dispensed as the branded product; compounded tesamorelin marketed by some 503A/503B pharmacies faces heightened FDA scrutiny, and gray-market "research-chemical, not for human use" vials are unapproved and unregulated for identity and purity.19 Branded tesamorelin is expensive — cash estimates commonly cited around $1,500-$2,500+ per month — though patient-assistance programs can reduce out-of-pocket cost for eligible HIV patients.18 It is not a DEA-scheduled controlled substance.

For athletes the picture is unambiguous. Tesamorelin is prohibited at all times (in- and out-of-competition) under the WADA Prohibited List, section S2.2 Growth Hormone Releasing Factors, explicitly named alongside CJC-1293, CJC-1295, and sermorelin, and in force on the 2026 Prohibited List effective January 1, 2026.1516 WADA-accredited labs detect GHRFs at picogram-per-milliliter levels and apply strict liability.17

Bottom line. Tesamorelin is the rare peptide secretagogue with genuine Grade-A human evidence — but only within a narrow lane: selective visceral-fat reduction and triglyceride improvement in HIV-associated lipodystrophy, with a maintenance-dependent effect. The HIV-NAFLD liver-fat data (A/B) and the single cognition RCT (B) are real but narrower, and the popular non-HIV anti-aging positioning (C-D) has no RCT support. Key uncertainties remain the long-term oncologic safety of sustained GH/IGF-1 elevation, durability, glucose effects in metabolically vulnerable users, and the entire non-HIV evidence gap. Where it has been studied, it works; outside that, the confident claims outrun the data. Regulatory facts here are current as of June 2026 and should be re-verified against the current FDA label and WADA list.